Description
Drostanolone Enanthate (Masteron E) is the long-acting heptanoate ester variant of Drostanolone. Pharmacology is identical to the propionate ester: 2α-methylated DHT derivative, no aromatase substrate, weak estrogen receptor antagonist with anti-estrogen residual action.
Per study reports the longer half-life of about 7-10 days brings a practical profile: two weekly injections suffice for stable plasma levels. This makes Masteron E the preferred compound in longer cutting or recomp research protocols where Masteron P with every-1-2-day injections would be impractical.
Pharmacology and side effect profile correspond to Masteron P: no aromatization, no water retention, mild anti-estrogen action, low hepatotoxicity. The milder action compared to Tren or classical anabolics makes Masteron E a “quality of life” compound in the research stack.
In recreational research practice Masteron E is typically used in 12-16 week cycles, often as accompanying compound to Test E and occasionally Tren E. The similar half-life of all three compounds allows synchronized injections twice per week.
Clinically Drostanolone (in propionate form) was used for breast cancer treatment. The enanthate form wasn’t clinically developed but exists primarily in underground pharmacy for recreational research purposes.
Drostanolone is on the WADA banned list.
You can order Drostanolone Enanthate as an oily injection solution in 10-pack at 200mg/ml.
This information is for research and educational purposes only. No medical recommendations.
Risks & Safety
Drostanolone Enanthate shares the mild risk profile of Masteron P - the effects described in the literature are manageable, but the DHT derivative remains an effective anabolic with a clear risk profile.
Documented in studies and the application literature:
- No aromatization: the 2-alpha-methylated DHT derivative is resistant to aromatization, estrogen-mediated effects and water retention are not documented. A weak anti-estrogen residual action is described.
- Androgenic effects: as a DHT derivative, mild androgenic effects such as acne and accelerated hair loss with genetic predisposition are documented.
- Suppression of endogenous production: Masteron moderately suppresses the HPG axis. Reduced endogenous testosterone production is documented, a test base is customary in research practice.
- Cardiovascular: the literature describes a worsening of the lipid profile, cardiac effects with long-term use are documented. Hepatotoxicity is low because there is no 17-alpha-methyl group.
Baseline bloodwork before, during and after a research protocol is strongly advised. This classification does not replace medical advice. Risk and responsibility for any actual use lie entirely with the buyer.
Studies
- Exploring the crystal and molecular structures of methenolone and drostanolone enanthate - Zeitschrift für Kristallographie 2024: crystallographic characterization of the heptanoate ester.
- Exploring the Polymorphism of Drostanolone Propionate - Molecules 2020: physicochemical characterization of the drostanolone ester family.
- Effect of drostanolone propionate on the binding of oestradiol and dihydrotestosterone by normal and malignant target tissues - European Journal of Cancer 1977: receptor-binding study of drostanolone (relevant for the shared pharmacology of the ester variants).
- New drostanolone metabolites in human urine by liquid chromatography time-of-flight tandem mass spectrometry - Steroids 2016: doping-detection study on drostanolone metabolites in human urine.
- Evidence of use of drostanolone, an anabolic steroid, at the time the subject committed a murder: Place of hair analysis - Toxicologie Analytique et Clinique 2021: forensic drostanolone detection in hair analysis.
